ALK rearrangement is associated with an increase in the incidence of BMs in patients with NSCLC, and the cumulative incidence of post-diagnosis BMs at 2 and 3 years is 45.5% and 58.4%, respectively [81]. This evidence concerns the gene ALK and non-small cell lung carcinoma.